Copyright © 2022 StrategyHelix Inc. All Rights Reserved.
Global 3D Bioprinting Market - Outlook and Forecast 2022-2027
The global 3D Bioprinting market is projected to experience a compound annual growth rate (CAGR) of 18.45% from 2021 to 2027. By 2027, it is expected to reach a value of USD 1.9 billion, a significant increase from USD 705.17 million in 2021. 3D bioprinting is an innovative technique that allows the production of biocompatible materials and complex 3D functional living tissues. Its impact on the field of medicine and healthcare has been substantial.
The focus of the 3D bioprinting market is on developing application-specific bio-inks and biomaterials, which are crucial for advancing the bio-printing of tissues and organs for clinical use. Bioprinters and bio-printed tissues have gained considerable interest in the medical and pharmaceutical industries. Additionally, bioprinting technology finds utility in various applications such as tissue engineering, regenerative medicine, transplantation, cancer research, drug screening, and high-throughput assays. Tissue engineering is currently the most recognized application of bioprinting, where bioprinters are used to manufacture scaffolds and create anatomically accurate patient-specific constructs. In vitro bio-printed tissues, including skin, nerves, and bones, have been successfully implanted in animals to evaluate their functionality, neovascularization, and integration with the host. The future application of bioprinting is expected to be predominantly in organ transplantation and drug and toxicity screening.
|No. of Pages||
USD 1947 Mn incremental growth between 2021 and 2026
Component, Application, Material, End-User, and Geography
|No. of Companies Mentioned||
4D bioprinting has emerged as a new field in the markets of regenerative medicine and tissue engineering, offering potential solutions to the limitations of 3D printing. Compared to 3D printing, 4D printing provides advantages such as the rapid growth of smart and multi-materials, more flexible and deformable structures, and expanded applications for both 4D and 3D printing. The development of 4D bioprinting shows promise in disease management and healthcare innovation.
The bioprinting market has seen the emergence of numerous companies. Bioprinting has the potential to become the gold standard for tissue biofabrication in the field of regenerative medicine. Established companies make up approximately 80% of the market, while start-ups with strong economic growth account for the remaining 20%. Among the different types of bioprinters, extrusion-based bioprinters are the most widely used due to their lower cost and ease of use. Inkjet-based bioprinting technology is the second most common and is often included in extrusion-based bioprinters as an additional printing head. Stereolithography-based bioprinters are a recent addition to the industry and are known to offer the highest resolutions but are also among the most expensive options. The global bioprinting market is not only growing quantitatively but also witnessing diversification in terms of the developed technologies and offerings. Bioprinting companies are dispersed across all continents, with the United States playing a dominant role among all countries. Several companies globally manufacture commercially available 3D bioprinters, indicating rapid growth in the field of bioprinting and the entry of numerous start-ups. There is also a rapid increase in technological innovations associated with bioprinters and bio-inks.
One notable technological trend is the development of magnetic bioprinters, exemplified by the Russian company 3D Bioprinting Solutions. Another innovation is the Kenzan Bio-printing method developed by the Japanese company Cyfuse Biomedical, which allows the creation of scaffold-free tissues using spheroids.
Printing resolution, speed, and cost reduction are common challenges that need to be addressed in the future. Germany-based Cellbricks focuses on producing complex 3D-printed cell culture structures using a proprietary non-commercial stereolithography-based bioprinting platform. Some companies are also working on increasing system flexibility and the range of printable features by proposing bioprinters with more degrees of freedom. For instance, the American company Advanced Solutions has patented a six-axis robotic extrusion-based bioprinter arm, BioAssembleBot 400, which can load up to ten independent biomaterials during a single print run.
Poietis, a France-based bioprinting company, combines laser-assisted bioprinting with extrusion-based and inkjet-based technologies, supported by proprietary privacy impact assessment (PIA) software, to reconstitute a complete tissue in 3D with all its layers. Similarly, the Canada-based company Aspect Biosystems aims to achieve improved accuracy by developing microfluidic platforms equipped with an on-printhead crosslinking system capable of printing bioinks with a coaxial shell.
In 2018, Prellis Biologics, in collaboration with BIOC Group, introduced one of the first systems using two-photon stereolithography to the market. Named Holograph X, this system utilizes a multiphoton technology that enables the curing of millions of points in the bioink simultaneously, leading to printing speeds of up to 250,000 voxels/second. Other advanced technologies include high-resolution, high-speed, high-accuracy, and 4D bioprinters. Companies like Poietis and ROKIT Healthcare now offer 4D bioprinting systems. Poietis’s 4D bioprinter, NGB-R, is a laser-assisted system that combines four single-cell-resolution technologies: computer-assisted design, automated robotic bioprinting, in-line monitoring, and tissue formation modeling. It allows for versatile bioprinting, from individual cells to spheroids, as well as the incorporation of large biomaterials and hydrogels.
The market is segmented based on various factors, including component, application, material, end-user, geography.
Segmentation by Components
Segmentation by Application
Segmentation by Material
Segmentation by End-User
RO & AT
Segmentation by Geography
North America – US, Canada
Europe – Germany, France, UK, Italy, Spain
APAC – China, Japan, India, South Korea, Australia
Latin America – Brazil, Mexico, Argentina
Middle East & Africa – South Africa, Saudi Arabia, Turkey, UAE
The Research Organizations & Academic Institutes segment has generated the highest revenue of $276.1 million in 2021, consequently holding the largest market share in the bioprinting industry. This can be attributed to the dominance of North America in the market, where there is an increasing number of research organizations and academic institutes dedicated to bioprinting research and the adoption of bioprinting technologies.
In particular, numerous research organizations and academic institutes in the United States have actively embraced advanced bioprinting technologies. This trend is driven by their collaborations with leading industry players to develop 3D functional tissue and organ models. With a growing emphasis on tissue engineering, cell therapy, and gene therapy, the regenerative medicine companies’ segment is projected to witness significant growth during the forecast period, exhibiting the highest compound annual growth rate (CAGR) of 19.47%.
The rising number of medical device manufacturers worldwide has contributed to the increased demand for advanced technologies. Major medical device and pharmaceutical companies are focusing on enhancing their product portfolios on a global scale. The demand for bioprinting is expected to surge due to the insufficient supply of organs for transplantation. Moreover, the substantial increase in research and development investments and funding toward research organizations and start-up companies will create abundant growth opportunities in the forthcoming years.
Bio-printing technology has gained popularity among surgeons and patients in recent years due to its precise capabilities in planning and performing reconstructive surgeries. Consequently, key developers of bio-printing are expanding their product portfolios by introducing bioprinters and devices as part of their manufacturing strategies. This development is expected to foster market growth during the forecast period.
North America and Europe currently dominate the bio-printing market. Ongoing research in regenerative medicine and advancements in tissue engineering aim to regenerate damaged tissues and organs using bioprinting techniques. The increasing focus on regenerative and personalized medicine is driving the growth of the bio-printing market in North America and Europe. Numerous vendors are actively pursuing technological advancements in bioprinting, particularly in terms of enhancing printing resolution, speed, and cost reduction. These challenges will continue to be addressed in the coming years.
The global bioprinting market is characterized by moderate dynamism, with a small number of key international players and a substantial pool of emerging start-up vendors offering a wide range of bioprinters. Organovo Holdings, BICO, and Advanced Solutions (ASI) are the major players in this market. Many players are focused on developing technologically advanced bioprinters to expand their product portfolios.
Bioprinting vendors face significant competition from established companies and emerging firms, driving them to enhance their competitiveness. Moreover, the market is witnessing numerous product launches by various vendors, along with increased research and development activities. These factors enable vendors to expand their market presence, drive market growth, and maintain their market positions globally.
The growing funding and investments from public and private entities, including large corporations and governments, are expected to support the development of bioprinters for various therapeutic applications by emerging international companies and start-ups. Several start-ups are also developing 3D reconstruction software to assist researchers in the field of bioprinting, contributing to the overall growth of the bioprinting market. However, vendors still face challenges related to regulatory approvals and ethical considerations, which can restrict their growth in the market.
Key companies profiled in this report include Organovo Holdings, BICO, Advanced Solutions (ASI), Aspect Biosystems, BIOLIFE4D, Brinter, Cellbricks, CollPlant, Cyfuse Biomedical, 3D Bio-printing Solutions, 3D Systems, 3DBio Therapeutics, Desktop Metal, Foldink, Formlabs, FELIXprinters, Fluicell, GeSiM, Hangzhou Jienuofei Biotechnology, Inventia Life Science, LIfe SI, Medprin, Next Big Innovation Labs, Ourobionics, Poietis, Precise Bio, Prellis Biologics, ROKIT Healthcare, REGENHU, Stratasys, TissueLabs.
Key Questions Answered
HOW LARGE IS THE GLOBAL BIOPRINTING MARKET?
The size of the global bio-printing market is projected to reach USD 1.9 billion by 2027.
WHAT IS THE GROWTH RATE OF THE BIO-PRINTING MARKET?
The bio-printing market is expected to grow at a compound annual growth rate (CAGR) of 18.45%.
WHAT ARE THE DRIVING FACTORS BEHIND THE GROWTH OF THE BIO-PRINTING MARKET?
The primary growth factors in the bio-printing market include the increasing focus on regenerative medicine, technological advancements in bioprinting, and investments and funding for research.
WHO ARE THE KEY PLAYERS IN THE BIO-PRINTING MARKET?
The key players in the bio-printing market are Organovo Holdings, BICO, and Advanced Solutions (ASI).
WHAT ARE THE RECENT TRENDS IN THE BIO-PRINTING MARKET?
The recent trends in the market include the emergence of 4D bioprinting, the growing focus on developing bio-printed organs, and the increasing emphasis on personalized medicine.